The use of platelets in regenerative medicine and proposal for a new classification system: guidance from the SSC of the ISTH

P. Harrison, J. Alsousou, I. Andia, T. Burnouf, D. Dohan Ehrenfest, P. Everts, H. Langer, J. Magalon, R. Marck, P. Gresele

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Summary: Autologous and single-donor allogenic platelet preparations are increasingly being used in many areas of regenerative medicine. However, there are few properly controlled randomized clinical trials, and the preparation, content and characteristics of platelet preparations are generally poorly defined and controlled. The Platelet Physiology Subcommittee of the Scientific and Standardization Committee (SSC) of the ISTH formed a working party of experts with the aim of producing consensus recommendations for guidance on the use of platelets in regenerative medicine. Owing to a lack of investigations that provide definitive evidence for the efficacy, definition and use of different platelet preparations in regenerative medicine, there were insufficient data to develop evidence-based guidelines. Therefore, the RAND method was used, which obtains a formal consensus among experts particularly when scientific evidence is absent, scarce and/or heterogeneous. Using this approach, each expert scored as ‘appropriate’, ‘uncertain’ or ‘inappropriate’ a series of 45 statements about the practice of regenerative medicine with platelets, which included different sections on general aspects, platelet preparations, clinical trial design, and potential utility in different clinical scenarios. After presentation and public discussion at SSC meetings, the assessments were further refined to produce final consensus recommendations, which constitute the subject of the present report.

Original languageEnglish
Pages (from-to)1895-1900
Number of pages6
JournalJournal of Thrombosis and Haemostasis
Volume16
Issue number9
DOIs
Publication statusPublished - Sep 1 2018
Externally publishedYes

Fingerprint

Regenerative Medicine
Blood Platelets
Randomized Controlled Trials
Clinical Trials
Guidelines

ASJC Scopus subject areas

  • Hematology

Cite this

The use of platelets in regenerative medicine and proposal for a new classification system : guidance from the SSC of the ISTH. / Harrison, P.; Alsousou, J.; Andia, I.; Burnouf, T.; Dohan Ehrenfest, D.; Everts, P.; Langer, H.; Magalon, J.; Marck, R.; Gresele, P.

In: Journal of Thrombosis and Haemostasis, Vol. 16, No. 9, 01.09.2018, p. 1895-1900.

Research output: Contribution to journalArticle

Harrison, P, Alsousou, J, Andia, I, Burnouf, T, Dohan Ehrenfest, D, Everts, P, Langer, H, Magalon, J, Marck, R & Gresele, P 2018, 'The use of platelets in regenerative medicine and proposal for a new classification system: guidance from the SSC of the ISTH', Journal of Thrombosis and Haemostasis, vol. 16, no. 9, pp. 1895-1900. https://doi.org/10.1111/jth.14223
Harrison, P. ; Alsousou, J. ; Andia, I. ; Burnouf, T. ; Dohan Ehrenfest, D. ; Everts, P. ; Langer, H. ; Magalon, J. ; Marck, R. ; Gresele, P. / The use of platelets in regenerative medicine and proposal for a new classification system : guidance from the SSC of the ISTH. In: Journal of Thrombosis and Haemostasis. 2018 ; Vol. 16, No. 9. pp. 1895-1900.
@article{a6b8db35074b4f60a5f08e3485ccdf4b,
title = "The use of platelets in regenerative medicine and proposal for a new classification system: guidance from the SSC of the ISTH",
abstract = "Summary: Autologous and single-donor allogenic platelet preparations are increasingly being used in many areas of regenerative medicine. However, there are few properly controlled randomized clinical trials, and the preparation, content and characteristics of platelet preparations are generally poorly defined and controlled. The Platelet Physiology Subcommittee of the Scientific and Standardization Committee (SSC) of the ISTH formed a working party of experts with the aim of producing consensus recommendations for guidance on the use of platelets in regenerative medicine. Owing to a lack of investigations that provide definitive evidence for the efficacy, definition and use of different platelet preparations in regenerative medicine, there were insufficient data to develop evidence-based guidelines. Therefore, the RAND method was used, which obtains a formal consensus among experts particularly when scientific evidence is absent, scarce and/or heterogeneous. Using this approach, each expert scored as ‘appropriate’, ‘uncertain’ or ‘inappropriate’ a series of 45 statements about the practice of regenerative medicine with platelets, which included different sections on general aspects, platelet preparations, clinical trial design, and potential utility in different clinical scenarios. After presentation and public discussion at SSC meetings, the assessments were further refined to produce final consensus recommendations, which constitute the subject of the present report.",
author = "P. Harrison and J. Alsousou and I. Andia and T. Burnouf and {Dohan Ehrenfest}, D. and P. Everts and H. Langer and J. Magalon and R. Marck and P. Gresele",
year = "2018",
month = "9",
day = "1",
doi = "10.1111/jth.14223",
language = "English",
volume = "16",
pages = "1895--1900",
journal = "Journal of Thrombosis and Haemostasis",
issn = "1538-7933",
publisher = "Wiley-Blackwell",
number = "9",

}

TY - JOUR

T1 - The use of platelets in regenerative medicine and proposal for a new classification system

T2 - guidance from the SSC of the ISTH

AU - Harrison, P.

AU - Alsousou, J.

AU - Andia, I.

AU - Burnouf, T.

AU - Dohan Ehrenfest, D.

AU - Everts, P.

AU - Langer, H.

AU - Magalon, J.

AU - Marck, R.

AU - Gresele, P.

PY - 2018/9/1

Y1 - 2018/9/1

N2 - Summary: Autologous and single-donor allogenic platelet preparations are increasingly being used in many areas of regenerative medicine. However, there are few properly controlled randomized clinical trials, and the preparation, content and characteristics of platelet preparations are generally poorly defined and controlled. The Platelet Physiology Subcommittee of the Scientific and Standardization Committee (SSC) of the ISTH formed a working party of experts with the aim of producing consensus recommendations for guidance on the use of platelets in regenerative medicine. Owing to a lack of investigations that provide definitive evidence for the efficacy, definition and use of different platelet preparations in regenerative medicine, there were insufficient data to develop evidence-based guidelines. Therefore, the RAND method was used, which obtains a formal consensus among experts particularly when scientific evidence is absent, scarce and/or heterogeneous. Using this approach, each expert scored as ‘appropriate’, ‘uncertain’ or ‘inappropriate’ a series of 45 statements about the practice of regenerative medicine with platelets, which included different sections on general aspects, platelet preparations, clinical trial design, and potential utility in different clinical scenarios. After presentation and public discussion at SSC meetings, the assessments were further refined to produce final consensus recommendations, which constitute the subject of the present report.

AB - Summary: Autologous and single-donor allogenic platelet preparations are increasingly being used in many areas of regenerative medicine. However, there are few properly controlled randomized clinical trials, and the preparation, content and characteristics of platelet preparations are generally poorly defined and controlled. The Platelet Physiology Subcommittee of the Scientific and Standardization Committee (SSC) of the ISTH formed a working party of experts with the aim of producing consensus recommendations for guidance on the use of platelets in regenerative medicine. Owing to a lack of investigations that provide definitive evidence for the efficacy, definition and use of different platelet preparations in regenerative medicine, there were insufficient data to develop evidence-based guidelines. Therefore, the RAND method was used, which obtains a formal consensus among experts particularly when scientific evidence is absent, scarce and/or heterogeneous. Using this approach, each expert scored as ‘appropriate’, ‘uncertain’ or ‘inappropriate’ a series of 45 statements about the practice of regenerative medicine with platelets, which included different sections on general aspects, platelet preparations, clinical trial design, and potential utility in different clinical scenarios. After presentation and public discussion at SSC meetings, the assessments were further refined to produce final consensus recommendations, which constitute the subject of the present report.

UR - http://www.scopus.com/inward/record.url?scp=85052741334&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052741334&partnerID=8YFLogxK

U2 - 10.1111/jth.14223

DO - 10.1111/jth.14223

M3 - Article

AN - SCOPUS:85052741334

VL - 16

SP - 1895

EP - 1900

JO - Journal of Thrombosis and Haemostasis

JF - Journal of Thrombosis and Haemostasis

SN - 1538-7933

IS - 9

ER -